TGN 1412

Drug Profile

TGN 1412

Alternative Names: Anti-CD28 monoclonal antibody - TeGenero; CD28-SuperMAB™; TGN-1412

Latest Information Update: 19 Jun 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TeGenero
  • Class
  • Mechanism of Action CD28 antigen stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 26 Apr 2006 Discontinued - Phase-I for Cancer in United Kingdom (unspecified route)
  • 16 Mar 2006 Suspended - Phase-I for Cancer in United Kingdom (unspecified route)
  • 17 Nov 2003 Preclinical trials in Cancer in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top